Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects

1. Blood banking and transfusion medicine – the field, the discipline and the industry

2. Quality principles in Transfusion medicine

3. Regulatory issues in transfusion medicine

4. Role of the physician in the blood center

5. Blood donor, donation process and technical aspects of blood collection

6. Apheresis blood component collections

7. Recipient-specific blood donations

8. Adverse donor reactions (iron)

9. Component preparation and manufacturing

10. Serologic testing of donor products

11. Overview of infectious disease testing

12. HIV screening

13. Hepatitis B screening

14. Hepatitis C screening

15. WNV screening

16. Zika screening

17. Babesia screening

18. Syphilis, HTLV and Chagas screening

19. Bacterial mitigation of platelets

20. Role of the transfusion service physician

21. Pretransfusion testing

22. Antibody identification

23. Direct antiglobulin test

24. Molecular DNA based blood group typing

25. ABO and H blood group systems

26. RH and RhAg blood group system

27. KELL and KIDD blood group systems

28. MNS AND DUFFY blood group systems

29. LEWIS, I P1Pk and Glob blood group systems

30. Other blood group systems, collections, and antigens

31. Human platelet and neutrophil antigens

32. HLA Antigens

33. Red blood cells products

34. Plasma products

35. Platelet products (to include PAS if not previously mentioned; was mentioned In the 2nd edition)

36. Cryoprecipitate and fibrinogen concentrates

37. Granulocyte products

38. Albumin and related products

39. Human immunoglobuin preparations

40. Rh immune globulin

41. Coagulation Factor products

42. Platelet rich plasma

43. Convalescent plasma, including COVID convalescent plasma

42. Nonfactor therapies for bleeding disorders

44. Blood Pharming and alternative blood production methods

45. Irradiation of blood products

44. Leukoreduction of blood products

46. CMV-safe blood products

47. Frozen blood products

48. Washed blood products

49. Volume reduced blood products

50. Pathogen reduction technologies

51. Intrauterine, Neonatal and pediatric transfusion medicine

52. Perinatal transfusion medicine

53. AutoImmune hemolytic anemias

54. Transfusion management in patients with hemoglobinopathies

55. Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplantation

56. Transfusion of Patients Undergoing Solid Organ Transplantation

57. Transfusion support and hemostatic monitoring in patients connected to extracorporeal devices

58. Transfusion of patients receiving antithrombotic therapy

59. Blood transfusion in economically restricted and developing countries

60. Management of Patients Who Refuse Blood Transfusion

61. Platelet transfusion refractory patients

62. Massive transfusion

63. Patient blood management

64. Overview of adverse events and outcomes following transfusion

65. Febrile non-hemolytic transfusion reactions

66. Allergic transfusion reactions

67. Acute hemolytic transfusion reactions

68. Delayed hemolytic transfusion reactions

69. Transfusion-Associated Circulatory Overload

70. Transfusion-Related Acute Lung Injury

71. Septic transfusion reactions

72. Metabolic, hypotensive and other acute reactions and complications

73. Post transfusion purpura

74. Transfusion associated graft versus host disease

75. Transfusion related immunomodulation

76. Iron Overload

77. Transfusion transmitted diseases

78. Overview to therapeutic apheresis

79. Therapeutic plasma exchange

80. Therapeutic erythrocytapheresis

81. Therapeutic thrombocytapheresis

82. Therapeutic leukocytapheresis and adsorptive cytapheresis

83. Extracorporeal photopheresis

84. LDL apheresis

85. Immunoabsorption

86. COVID-19 & Apheresis

87. Therapeutic phlebotomy

88. Overview of cellular therapy

89. HPC products derived from bone marrow and peripheral blood

90. Cord blood banking (expansion)

91. Regenerative medicine (iPS)

92. Immunotherpy (T cells): CAR-T, TILs, gene therapy and more

93. Adverse events associated with HPC product infusion

94. Quality and regulatory issues in cellular therapy

95. Tissue banking in the hospital setting

96. Overview of the coagulation system

97. Approach to the patient with a bleeding disorder

98. Congenital thrombocytopenia

99. fetal and Neonatal alloimmune thrombocytopenia

100. Acquired neonatal thrombocytopenia

101. Bernard Soulier syndrome and other GPIb-IX-V related receptor defects

102. Glanzmann's thrombocytopenia

103. Other platelet glycoprotein disorders

104. Platelet storage-granule defects

105. Failure to release and aspirin-like defects

106. Other Platelet abnormalities

107. Acquired platelet disorders

108. Acute (childhood) ITP

109. Chronic ITP

110. Drug induced thrombocytopenia

111. Heparin induced thrombocytopenia

112. Vaccine Induced Thrombotic Immune Thrombocytopenia

113. Autoimmune lymphoproliferative syndrome

114. Hemolytic uremic syndrome

115. Thrombotic thrombocytopenic purpura

116. Antiphospholipid syndrome

117. Von Willebrand Disease

118. Hemophilia A

119. Hemophilia B

120. Congenital disorders of fibrinogen

121. Factor XIII, D α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 deficiencies

122. Factor XI deficiency

123. Factor VII deficiency

124. Factor II, factor V, and factor X deficiencies

125. Bleeding disorders in pregnancy

126. Vascular bleeding disorders

127. Hemostasis in Liver Disease

128. Bleeding risks with Vitamin K deficiency

129. Bleeding risks with cardiac disease

130. Bleeding risks with renal disease

131. Bleeding risks with cancer

132. Disseminated intravascular coagulopathy

133. coagulopathy in sickle cell disease and other hemoglobiniopathies

134. COVID coagulopathy

135. Thrombosis in COVID Coagulopathy---Anticoagulation guidelines

136. Bleeding in COVID coagulopathy

137. Acquired coagulation factor inhibitors

138. Overview of purposes of hemostasis testing and common sources of error

139. Pediatric reference ranges in coagulation testing 

140. Prothrombin Time

141. Activated Partial Thrombolplastin Time

142. Mixing studies

143. Coagulation Factor Testing

144. Testing of Nonfactor therapies: emicizumab

145: Testing of Nonfactor therapies: inhibitors of anticoagulant pathways (fitusiran and concizumab)

146. Specific Factor Inhibitor Testing

147. Thrombin time and Fibrinogen Evaluation

148. laboratory diagnosis of inherited von Willebrand Disease

149. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome

150. Laboratory Assessment of Treatment of von Willebrand’s Disease

151. Measurement of platelet count, mean platelet volume, and reticulated platelets

152. Platelet Function Analyzer

153. thromboelastography/thromboelastometry

154. Platelet Aggregation Studies

155. Laboratory Diagnosis of Platelet Functional Defects

156. Confirmatory testing for diagnosis of platelet disorders

157. Platelets in COVID coagulopathy

158. Anti-platelet Therapy Monitoring

159. Laboratory evaluation of factor XIII deficiency

160. Fibrinolytic testing

161. Age-adjusted D-Dimer cut offs to rule out PE/ VTE 162. Laboratory techniques in fibrinolysis testing

163. Laboratory evaluation of long-term thrombophilic disorders

164. Thrombophilia testing in children

165. Antithrombin Testing

166. Protein C deficiency evaluation

167. Protein S deficiency evaluation

168. testing for Activated Protein C Resistance

169. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in inherited thrombophilia

170. Chronic elevated levels of Factor VIII and other coagulation factors

171. Laboratory Monitoring for Heparins, fondaparinux, direct thrombin inhibitors, and oral anti-Xa medications

172: DOAC interferences in coagulation testing

173. Laboratory testing in patients receiving DOAC antidotes

174. Laboratory support for warfarin monitoring

175. Molecular testing in Coagulation

176. Acquired prothrombotic conditions

177: Ventricular assist device: anticoagulation monitoring

178. Laboratory Evaluation of Heparin-Induced Thrombocytopenia

179. Laboratory Evaluation of Thrombotic Thromcytopenic Purpura

180. D-Dimer testing in COVID coagulopathy

181. Other coagulation tests in COVID coagulopathy

182. Laboratory diagnosis of lupus anticoagulant and anti-phopholipid antibodies

183. Lupus anticoagulant testing in COVID-19

184. Circulating microparticles

185. Thrombin Generation Assays

186. Laboratory testing of contact factors

187. Contact factors and complements

188. Monitoring of new anticoagulants---inhibitors of contact factors

189. Reference ranges in transgender

Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Fourth Edition continues to be the only "pocket-size" quick reference for pathology and transfusion medicine for residents and fellows. It is helpful to all physicians and allied health professionals who order and administer blood components, cellular therapies, specialized factors for hemostatic abnormalities, coagulation testing, and those who consult and care for these often very ill patients. This book is ideal for pathology, medicine, surgery, and anesthesia residents, transfusion, hematology, and anesthesia fellows, and certified and specialized practitioners, as well as medical technologist in transfusion, cellular therapy, hematology, and coagulation. This new edition covers the many new developments that have occurred since the previous edition to include new blood products, new indications, or clinical conditions in which blood products are used. Similarly, new hemostasis testing is introduced as well as new clinical scenarios due the COVID-19 pandemic that area relevant to hemostasis and transfusion medicine. This includes COVID coagulopathy, Vaccine Induced Thrombotic Immune Thrombocytopenia, Pediatric reference range in coagulation testing, Platelet rich plasma and MNC products – CAR-T cells.

• Includes COVID-19 coagulopathy and Vaccine Induced Thrombotic Immune N94 Thrombocytopenia
• Provides all information regarding the clinical and laboratory aspects of Transfusion Medicine and Hemostasis in one place
• Presents user-friendly, up-to-date information in a book that can be carried around either to the lab or bedside

Beth H. Shaz, MD, is Chief Medical and Scientific Officer and Executive Vice President, New York Blood Center and Adjunct Assistant Professor, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

Christopher D. Hillyer, MD, is President and Chief Executive Officer, New York Blood Center and Professor, Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Joseph (Yossi) Schwartz, MD, MPH, is Professor of Pathology, Molecular and Cell–based Medicine, Icahn School of Medicine, Mount Sinai, NY, USA

Morayma Reyes Gil, MD, PhD, is Director of Hematology and Coagulation Laboratories, Montefiore Medical Center and Associate Professor, Department of Pathology and Laboratory Medicine, Albert Einstein College of Medicine, New York, NY, USA